#CIBMTR
📢 #Tandem27 registration is open!

Join ASTCT and CIBMTR for the latest research, emerging therapies, and advances in transplantation and cellular therapy.

📍 Orlando, FL | 📅 Feb. 17-20, 2027

Register: www.tandemmeetings.com/Registration...
October 7, 2026 at 6:39 PM
NEW: CIBMTR Research

Fertility preservation in 2026: Current landscape in Europe and the United States for children and adolescents undergoing HCT-recommendations on behalf of the Westhafen Intercontinental Group

Read more:
🔗pubmed.ncbi.nlm.nih.gov/42120917/
October 1, 2026 at 6:00 PM
NEW: CIBMTR Research

Haploidentical versus HLA-matched unrelated donors for HCT in acute leukemia

Read more:
🔗 pubmed.ncbi.nlm.nih.gov/42323086/
September 29, 2026 at 6:00 PM
Abstract submission for #Tandem27 is now open! ASTCT and CIBMTR invite you to share your research with your HCT, cell, and gene therapy colleagues in Orlando, FL, February 17-20, 2027! Learn more: www.tandemmeetings.com/Abstracts/Ab...
@astct.bsky.social
September 25, 2026 at 4:00 PM
NEW: CIBMTR Research
Access challenges in alloHCT: Identifying at-risk US states by exploring social vulnerability, physician density, and unmet need

Read more:
🔗pubmed.ncbi.nlm.nih.gov/42372215/
September 24, 2026 at 6:00 PM
NOW AVAILABLE: 2014-2024 Non-Malignant Summary Slides. These slides detail the clinical practices, trends, and survival outcomes following HCT and cellular therapy, including gene therapy for non-malignant diseases. Learn more: cibmtr.org/CIBMTR/Resou...
September 24, 2026 at 3:40 PM
NEW: CIBMTR Research
Classical HLA allele and haplotype frequency estimates in US populations

Read more:
🔗 pubmed.ncbi.nlm.nih.gov/42341485/
September 22, 2026 at 6:00 PM
NEW: CIBMTR Research
Newborn screening reduces survival disparities in SCID after stem cell transplant: A PIDTC report
Read more:
🔗pubmed.ncbi.nlm.nih.gov/42416786/
September 17, 2026 at 6:00 PM
The wait is over. Registration for #Tandem27 is officially open!

Join ASTCT and CIBMTR in Orlando, February 17-20, 2027, for the premier event in HCT, cellular therapy, and gene therapy.

📍 Orlando, FL
📅 February 17-20, 2027

Secure your spot today: www.tandemmeetings.com/Registration...
September 16, 2026 at 8:33 PM
Could your research question change practice?

Don't miss your chance to shape future research. There's only 1 week left to submit a proposal for consideration for a CIBMTR Working Committee study.

📅 Deadline: Monday, Sept. 21
🔗cibmtr.org/CIBMTR/Resea...
September 16, 2026 at 3:00 PM
NEW: CIBMTR Research
Infection burden in mismatched unrelated donor HCT: Results from the ACCESS Trial
Read more:
🔗pubmed.ncbi.nlm.nih.gov/42448319/
September 10, 2026 at 6:00 PM
💡 Your next research idea could help shape the future of transplantation and cellular therapy.

CIBMTR is accepting Working Committee Study proposals from investigators interested in leading impactful observational research.

📅 Deadline: Monday, Sept. 21

Submit today: cibmtr.org/CIBMTR/Resea...
September 9, 2026 at 3:00 PM
Have a research question that could advance the field of cellular therapy?

Submit a CIBMTR Working Committee study proposal for consideration at the 2027 Tandem Meetings.

📅 Deadline: Monday, Sept. 21

🔗 cibmtr.org/CIBMTR/Resea...
September 3, 2026 at 3:00 PM
Abstract submission for #Tandem27 is now open! ASTCT and CIBMTR invite you to share your research with your HCT, cell, and gene therapy colleagues in Orlando, FL, February 17-20, 2027! Learn more www.tandemmeetings.com/Abstr.../Abs...
@astct.bsky.social
September 2, 2026 at 6:00 PM
Correction: Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study - Blood Cancer Journal
In this article, the author’s name, ‘Larry D. Anderson, Jr’ has been published erroneously as ‘Larry Anderson’. The original article has been corrected. Author information These authors contributed equally: Doris K. Hansen, Danai Dima, Hira Mian. These authors jointly supervised this work: Surbhi Sidana, Krina K. Patel. Authors and Affiliations Doris K. Hansen, Abu-Sayeef Mirza & Taiga Nishihori University of Washington/Fred Hutchinson Cancer Center, Seattle, WA, USA Danai Dima, Aimaz Afrough & Rahul Banerjee Hira Mian Jakob Devos, Temitope Oloyede & Othman S. Akhtar Ruta Brazauskas, Binod Dhakal, Meera Mohan, Ravi Narra & Othman S. Akhtar Nausheen Ahmed Larry D. Anderson Jr Jesus G. Berdeja Aram Bidikian & Lohith Gowda Ajoy Dias OhioHealth, Columbus, OH, USA Yvonne Efebera Muhammad Salman Faisal Hamza Hashmi, Heather Landau & Saad Usmani Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
dlvr.it
August 31, 2026 at 12:47 PM
Abstract submission for #Tandem27 is now open! ASTCT and CIBMTR invite you to share your research with your HCT, cell, and gene therapy colleagues in Orlando, FL, February 17-20, 2027! Learn more www.tandemmeetings.com/Abstr.../Abs...
@astct.bsky.social
August 21, 2026 at 3:30 PM
NEW: CIBMTR Research

Real-world heterogeneity in the prognostic value of pre-transplant flow cytometry measurable residual disease in AML in first complete remission: CIBMTR analysis

Read more:
🔗pubmed.ncbi.nlm.nih.gov/42206435/
August 20, 2026 at 6:00 PM
Clinical trial for mismatched transplant helps more people. Read about this CIBMTR study to learn more: cibmtr.org/Patient-Summ...
August 18, 2026 at 3:13 PM
NEW: CIBMTR Research
IMPACT for patients with inborn errors of immunity from the Primary Immune Deficiency Treatment Consortium

Read more:
🔗pubmed.ncbi.nlm.nih.gov/42242424/
August 13, 2026 at 6:00 PM
NEW: CIBMTR Research

Comparison of fludarabine versus bendamustine as a lymphodepleting chemotherapy prior to CAR T for large cell lymphoma
Read more:

🔗pubmed.ncbi.nlm.nih.gov/42341926/
August 6, 2026 at 6:00 PM
CIBMTR and the MCW Division of Hematology and Oncology invite applications for a faculty position as a CIBMTR Senior Scientific Director. Learn more about and apply for this important position: mcw.wd503.myworkdayjobs.com/en-US/Extern...
August 5, 2026 at 5:04 PM
🔬 What's new at CIBMTR?

The August 2026 Newsletter is here! Explore research highlights from our working committees, updates on adoptive cellular therapies & gene therapy reporting, 2025 US Summary Slides, and a preview of #Tandem27. 📬

cibmtr.org/CIBMTR/About...
August 4, 2026 at 3:00 PM
Tisagenlecleucel 真實世界數據
CIBMTR 報告:初始 CR 率 85.5%,12 個月的反應持續 60.9%、EFS 52.4%、OS 77.2%。
CRS 發生率 55%,其中 ≥3 級佔 16.1%,處置以 tocilizumab 與類固醇為主。
關鍵:達到緩解後「只有少數」接續移植 —— 說 90% 都去移植是錯的,CAR-T 本身即具治癒意圖。
#血液專科
https://hema-2026.hsiehting.com/q/110-076
August 4, 2026 at 7:35 AM
NEW: CIBMTR Research

Infections within 100 days of idecabtagene vicleucel and impact on survival for relapsed/refractory multiple myeloma: A CIBMTR analysis
Read more:

🔗pubmed.ncbi.nlm.nih.gov/42364732/
July 30, 2026 at 6:00 PM
NEW: CIBMTR Research
Quantile regression of the relationship between demographic factors and leukocyte telomere length, measured by Southern blot and qPCR Read more:
🔗pubmed.ncbi.nlm.nih.gov/41619133/
July 22, 2026 at 6:00 PM